Core Insights - Dongyao Pharmaceutical-B (01875.HK) reported a mid-year performance for 2025, with revenue approximately 489 million and net profit around 4.06 million [1] - The net cash flow from operating activities remained positive, amounting to 34.83 million in the first half of 2025, representing a year-on-year increase of 25% [1] Financial Performance - Revenue for the first half of 2025 was approximately 489 million [1] - Net profit for the same period was about 4.06 million [1] - Operating cash flow for the first half of 2025 was 34.83 million, showing a 25% increase compared to the previous year [1]